Search Results - "Zarba, Juan J"

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial by Sternberg, Cora N, Davis, Ian D, Mardiak, Jozef, Szczylik, Cezary, Lee, Eunsik, Wagstaff, John, Barrios, Carlos H, Salman, Pamela, Gladkov, Oleg A, Kavina, Alexander, Zarbá, Juan J, Chen, Mei, McCann, Lauren, Pandite, Lini, Roychowdhury, Debasish F, Hawkins, Robert E

“…Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This…”
Get full text

Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer by MONK, Bradley J, MAS LOPEZ, Luis, ZARBA, Juan J, OAKNIN, Ana, TARPIN, Carole, TERMRUNGRUANGLERT, Wichai, ALBER, Jacquelyn A, JIE DING, STUTTS, Melissa W, PANDITE, Lini N

“…Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and…”
Get full text

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study by Kowalyszyn, Ruben D, Fein, Luis E, Richardet, Martin E, Varela, Mirta S, Ortiz, Eduardo, Micheri, Cristian, Zarba, Juan J, Kahl, Susana, Klimovsky, Ezequiel, Federico, Andrea A, Cassini, Jorge H, Cortese, Gustavo, Lago, Nestor

“…This study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with…”
Get full text

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update by Sternberg, Cora N, Hawkins, Robert E, Wagstaff, John, Salman, Pamela, Mardiak, Jozef, Barrios, Carlos H, Zarba, Juan J, Gladkov, Oleg A, Lee, Eunsik, Szczylik, Cezary, McCann, Lauren, Rubin, Stephen D, Chen, Mei, Davis, Ian D

“…Abstract Background In this randomised phase III study (VEG105192; NCT00334282 ), pazopanib previously demonstrated statistically and clinically meaningful…”
Get full text

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix by Dueñas-González, Alfonso, Zarbá, Juan J., Patel, Firuza, Alcedo, Juan C., Beslija, Semir, Casanova, Luis, Pattaranutaporn, Pittayapoom, Hameed, Shahid, Blair, Julie M., Barraclough, Helen, Orlando, Mauro

“…To determine whether addition of gemcitabine to concurrent cisplatin chemoradiotherapy and as adjuvant chemotherapy with cisplatin improves progression-free…”
Get full text

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial by Sternberg, Cora N, Davis, Ian D, Mardiak, Jozef, Szczylik, Cezary, Lee, Eunsik, Wagstaff, John, Barrios, Carlos H, Salman, Pamela, Gladkov, Oleg A, Kavina, Alexander, Zarbá, Juan J, Chen, Mei, McCann, Lauren, Pandite, Lini, Roychowdhury, Debasish F, Hawkins, Robert E

“…PURPOSE Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit…”
Get full text

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study) by Gómez, Henry L, Neciosup, Silvia, Tosello, Célia, Mano, Max, Bines, José, Ismael, Gustavo, Santi, Patrícia X, Pinczowski, Hélio, Nerón, Yeni, Fanelli, Marcello, Fein, Luis, Sampaio, Carlos, Lerzo, Guillermo, Capó, Adolfo, Zarba, Juan J, Blajman, César, Varela, Mirta S, Martínez-Mesa, Jeovany, Werutsky, Gustavo, Barrios, Carlos H

“…Micro-Abstract In LACOG 0801 phase II study 142 patients with HER2+ MBC with progression after taxane were randomized between Lapatinib (L) combined with…”
Get full text

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update by STERNBERG, Cora N, HAWKINS, Robert E, MCCANN, Lauren, RUBIN, Stephen D, MEI CHEN, DAVIS, Ian D, WAGSTAFF, John, SALMAN, Pamela, MARDIAK, Jozef, BARRIOS, Carlos H, ZARBA, Juan J, GLADKOV, Oleg A, LEE, Eunsik, SZCZYLIK, Cezary

Get full text

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial by STERNBERG, Cora N, DAVIS, Ian D, ZARBA, Juan J, MEI CHEN, MCCANN, Lauren, PANDITE, Lini, ROYCHOWDHURY, Debasish F, HAWKINS, Robert E, MARDIAK, Jozef, SZCZYLIK, Cezary, LEE, Eunsik, WAGSTAFF, John, BARRIOS, Carlos H, SALMAN, Pamela, GLADKOV, Oleg A, KAVINA, Alexander

Get full text